Immunoglobulin National Society (IgNS) 9th National Conference 2020
Virtual Event Healix is excited to present our research data on Cutaquig® at the Immunoglobulin National Society (IgNS) 9th National Conference 2020. Speak with presenting author Lucinda J. Van Anglen, B.S., Pharm.D., during the IgNS Poster Session on Monday, October...
Healix Demonstrates Hospital Avoidance with Provision of Outpatient Antimicrobial Therapy (OPAT): A Leader in the Field for Over 30 Years
SUGAR LAND, TX – (July 9, 2020) Healix Infusion Therapy, LLC has demonstrated success in achieving hospital avoidance when providing outpatient antimicrobial therapy (OPAT) to patients with serious infections through physician offices. Healix manages over 70...
Healix Announces First Real-World Study of Immune Globulin Subcutaneous 16.5% (Cutaquig®) Featured in the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
SUGAR LAND, TX – (May 7, 2020) Healix Infusion Therapy is pleased to announce that its collaborative research study regarding Immune Globulin Subcutaneous 16.5% (Cutaquig®) is now accessible in the AAAAI Annual Meeting Virtual Poster Hall. The study by authors Richard...
Happy National Nurses Week (May 6-12) from Healix!
The team at Healix would like to recognize and thank nurses across the nation for their dedication to the nursing profession and the time they sacrifice away from their loved ones to care for those in need. Nurses play a critical role not only in our healthcare system...
Recent Comments